CN105087497B - Hybridoma cell strain ZJEB8-01, anti-Ebola virus GP protein monoclonal antibody, and preparation and application thereof - Google Patents
Hybridoma cell strain ZJEB8-01, anti-Ebola virus GP protein monoclonal antibody, and preparation and application thereof Download PDFInfo
- Publication number
- CN105087497B CN105087497B CN201510520454.6A CN201510520454A CN105087497B CN 105087497 B CN105087497 B CN 105087497B CN 201510520454 A CN201510520454 A CN 201510520454A CN 105087497 B CN105087497 B CN 105087497B
- Authority
- CN
- China
- Prior art keywords
- ebola virus
- monoclonal antibody
- protein
- zjeb8
- ebola
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004408 hybridoma Anatomy 0.000 title claims abstract description 39
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 38
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 title claims abstract description 34
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 26
- 241000700605 Viruses Species 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title abstract description 5
- 108010088468 Ebola virus envelope glycoprotein Proteins 0.000 claims abstract description 27
- 238000001514 detection method Methods 0.000 claims description 14
- 238000002965 ELISA Methods 0.000 claims description 8
- 238000001262 western blot Methods 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000007689 inspection Methods 0.000 claims description 2
- 238000002331 protein detection Methods 0.000 claims 1
- 241001115402 Ebolavirus Species 0.000 abstract description 10
- 230000035945 sensitivity Effects 0.000 abstract description 8
- 238000011161 development Methods 0.000 abstract description 4
- 230000003472 neutralizing effect Effects 0.000 abstract description 4
- 238000012163 sequencing technique Methods 0.000 abstract description 4
- 230000003248 secreting effect Effects 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 2
- 230000009466 transformation Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 32
- 238000000034 method Methods 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 230000000295 complement effect Effects 0.000 description 12
- 238000005406 washing Methods 0.000 description 12
- 206010003445 Ascites Diseases 0.000 description 10
- 208000030820 Ebola disease Diseases 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 238000004321 preservation Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 206010035226 Plasma cell myeloma Diseases 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 201000000050 myeloid neoplasm Diseases 0.000 description 9
- 241001529936 Murinae Species 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 230000001461 cytolytic effect Effects 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 210000003024 peritoneal macrophage Anatomy 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000007910 cell fusion Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 229940124722 Ebola vaccine Drugs 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 238000001261 affinity purification Methods 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 239000012148 binding buffer Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000008118 PEG 6000 Substances 0.000 description 2
- 206010035148 Plague Diseases 0.000 description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- -1 9-fluorenylmethyloxycarbonyl Chemical group 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000018297 Immunoglobulin subtype Human genes 0.000 description 1
- 108050007411 Immunoglobulin subtype Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 102000005937 Tropomyosin Human genes 0.000 description 1
- 108010030743 Tropomyosin Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000003163 cell fusion method Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000001728 clone cell Anatomy 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000003771 laboratory diagnosis Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention relates to a hybridoma cell strain ZJEB8-01, an Ebola virus GP protein resistant monoclonal antibody, and preparation and application thereof. The hybridoma cell strain ZJEB8-01 can be used for secreting the anti-Ebola virus GP protein monoclonal antibody. The monoclonal antibody has high specificity and sensitivity with the 412-. The invention also completes the sequencing of the monoclonal antibody, develops the neutralizing antibody capable of neutralizing the Ebola virus for the humanized transformation of the sequence of the monoclonal antibody, and lays a material foundation for the later development of the neutralizing antibody for clinical treatment of the Ebola virus.
Description
Technical field
The present invention relates to biological technical fields, and in particular to hybridoma cell strain ZJEB8-01, anti-Ebola virus GP eggs
White monoclonal antibody and its preparation and application.
Background technology
Ebola disease viral disease is the lethal hemorrhage heat as caused by infecting Ebola virus.1976, Ebola virus existed
Zaire breaks out for the first time, after broken out on a small scale in central Africa region successively, end 2013, cause 2387 human hairs sick altogether, it is dead
1310, case fatality rate 54.9%.Ebola virus is broken out again within 2014, sweeps across West Africa, and crosses over continent, the U.S., Britain, west
Ebola's case occurs in succession for class's tooth.End on May 27th, 2015, share 26969 cases, die of illness 11135, case fatality rate is still
Up to 41.3%.From Ebola's the first explosion so far, pass by nearly 40 years, still controlled in the world without special at present
Treatment means and the vaccine for Clinical practice.Ebola disease viral disease has become international serious infectious diseases, Ebola virus
Quickly, control of the exploration of efficient diagnosis and therapy to ebola disease viral disease and the safety to the mankind are most important.
The diagnosis of classical Ebola virus infection relies on quantitative PCR technique, but in Ebola plague area, due to economic item
Part falls behind, and is not the expense that each countries and regions can bear corresponding instrument, thus the restricted application of the diagnostic method,
It is not applied for whole areas.Thus develop a kind of monoclonal antibody production of quick, sensitive, cheap Ebola virus detection
Product, it is possible to be widely used in plague area, can broadly find that Ebola infects earlier, carry out isolation treatment ahead of time, subtract
The diffusion of few Ebola virus.
Ebola disease viral disease does not still have specific therapy at present.Up to the present a kind of the anti-of special efficacy is not found
Ebola disease cytotoxic drug.Although having now been developed the drug ZMapp of three kinds of antibody mixing in the world, therapeutic effect still has
It limits and imprecise.If the antibody lacks validity and security in the clinical I phases, then people will face can use again without medicine
Condition in addition lacked can be spare drug.The thus continual exploitation of Ebola's monoclonal antibody is controlled for ebola disease viral disease
It treats and more alternative antibody is provided, just can greatly increase the possibility for the treatment of ebola disease viral disease.
In conclusion a kind of quick, sensitive Ebola virus diagnosis antibody of development and development one kind are expected to be used for clinic
The ebola antibody for the treatment of is extremely urgent.
The content of the invention
First purpose of the invention is to provide hybridoma cell strain ZJEB8-01, and the hybridoma cell strain is by Chinese allusion quotation
Type culture collection (CCTCC) preservation;Address:Wuhan, China Wuhan University;Preservation date:On June 3rd, 2015;Preservation
Number is:CCTCC NO:C201583.It is with SEQ ID NO in sequence table:Anti- Ebola virus GP protein Dan Ke shown in 1
(wherein, 1-57 is leader to grand heavy chain of antibody coding gene sequence, and 58-147 is framework region 1, and 148-162 is complementary determining region
1,163-204 is framework region 2, and 205-255 is complementary determining region 2, and 256-351 is framework region 3, and 352-366 is complementary determining region
3,367-399 be framework region 4) and sequence table in SEQ ID NO:Anti- Ebola virus GP protein monoclonal antibody shown in 2 is light
(wherein, 1-60 is leader to chain encoding gene order, and 61-129 is framework region 1, and 130-177 is complementary determining region 1,178-222
For framework region 2,223-243 is complementary determining region 2, and 244-339 is framework region 3, and 340-366 is complementary determining region 3,367-396
For framework region 4).
Second purpose of the invention is to provide a kind of anti-Ebola virus GP protein monoclonal antibody, it is by deposit number
For:CCTCC NO:The hybridoma cell strain ZJEB8-01 secretions of C201583.SEQ in its heavy chain amino acid sequence such as sequence table
ID NO:Shown in 3, SEQ ID NO in light-chain amino acid sequence such as sequence table:Shown in 4.The monoclonal antibody hypotype is IgG1, κ
Type has high specificity and sensitivity with the Antigenic Peptide of Ebola virus GP protein, and the Antigenic Peptide is Ebola virus GP
The 412-431 amino acids sequences of albumen, such as SEQ ID NO:Shown in 5:DNDSTASDTPPATTAAGPLK.
3rd purpose of the invention is to provide the preparation method of above-mentioned anti-Ebola virus GP protein monoclonal antibody, including
Following steps:
(1) mouse immune:The BALB/C mice of 6 week old is selected, with the Antigenic Peptide (ebola disease of Ebola virus GP protein
The 412-431 amino acid sequences of malicious GP albumen:DNDSTASDTPPATTAAGPLK) mouse is immunized;Every mouse with
Femoribus internus intramuscular injection is immunized after the Antigenic Peptide mixing adjuvant of 100ug, is immunized once again after the 21st day;3rd booster immunization 3
It is used to merge after it;
(2) culture of murine myeloma cell SP2/0:Culture murine myeloma cell SP2/0 simultaneously makes its holding good
Growth conditions are used for hybridoma cell fusion;
(3) cell fusion:It is thin using BALB/C mice peritoneal macrophage as raising using polyethylene glycol cell fusion method
Born of the same parents, in fusion the previous day, inoculation BALB/C mice peritoneal macrophage is in 96 well culture plates, the HAT culture mediums training containing 20%FCS
It supports one day, the mouse got ready in step (1) is put to death, obtain spleen lymphocyte;Mouse myeloma in collection step (2) is thin
Born of the same parents SP2/0 centrifuges above two mixing with cells, is then merged with polyethylene glycol mediated cell, and the cell after fusion is suitably dilute
It releases, is seeded to feeder cells culture plate, felicity condition culture;
(4) screening of hybridoma:Cultivate above-mentioned culture, cell colony grow to size it is suitable when, draw cell
Culture supernatant does Identification of the antibodies, screening positive clone;
(5) cloning of hybridoma:With the positive hybridoma of limiting dilution assay clone, will be diluted to certain close
The cell inoculation of degree is to 96 porocyte culture plates, and making every hole, only there are one cell growths;The hole for forming cell colony is taken in culture
Clear liquid is cooked MBP enzyme linked immuno-adsorbent assay (ELISA), screening and identification positive colony;Repeated cloning several times, until hybridoma is thin
The positive porosity of born of the same parents reaches 100%;
(6) ascites is induced:1 week before hybridoma is inoculated with, norphytane every is injected intraperitoneally to BALB/C mice
0.5ml, then every inoculation well-grown 5 × 106A positive hybridoma cell collects ascites centrifugation after 10 days, measure anti-
Body potency;
(7) purifying of monoclonal antibody:The monoclonal antibody in ascites is purified using Protein G affinity purifications.
Through monoclonal antibody immunity tropomyosin isoform analysis shows that the Antibody types that the hybridoma generates are IgG1, κ
Type.
4th purpose of the invention is to provide hybridoma cell strain ZJEB8-01 and is producing anti-Ebola virus GP protein Dan Ke
Application in grand antibody.The present invention is by immune BALB/C mice spleen lymphocyte and murine myeloma cell SP2/0 through melting
The hybridoma cell strain ZJEB8-01 of the anti-Ebola virus GP protein monoclonal antibody of generation close, screen, obtained after clone, warp
3 time clonings, persistently more than June, secretory antibody is stablized for culture.The cell line is through liquid nitrogen cryopreservation, well-grown after recovery, antibody
Secretion has no decline.ELISA indirect methods measure ZJEB8-01 culture supernatants potency as 1:320, titer of ascites 1:25600.
In China typical culture collection center (CCTCC) preservation, preserving number is ZJEB8-01:CCTCC No.C201583.
5th purpose of the invention is to provide above-mentioned anti-Ebola virus GP protein monoclonal antibody and is preparing ebola disease
Application in malicious GP protein assay reagents, the detection reagent is in the Ebola's vaccine culture solution for loading Ebola virus GP protein
Or detected in other body fluid or culture solution for generating Ebola virus GP protein, it is realized by following approach:
1. using anti-Ebola virus GP protein monoclonal antibody as probe, pass through western blotting method with SDS-PAGE electrophoresis
(Western Blot) reflects to the situation of GP albumen in Ebola's vaccine culture solution of loading Ebola virus GP protein
It is fixed.
2. using anti-Ebola virus GP protein monoclonal antibody as detection antibody, pass through enzyme-linked immunosorbent assay
(ELISA) GP protein expression levels are carried out qualitative and quantified in Ebola's vaccine culture solution to loading Ebola virus GP protein
Analysis.
Beneficial effects of the present invention:
1st, hybridoma cell strain ZJEB8-01 of the present invention, through 3 time clonings, persistently culture secretes anti-Ebola more than June
Virus GP protein monoclonal antibody is stablized;The cell line is through liquid nitrogen cryopreservation, well-grown after recovery, and antibody-secreting has no decline.
2nd, the anti-Ebola virus GP protein monoclonal antibody of the present invention and the Antigenic Peptide of Ebola virus GP protein have height
Specificity and sensitivity, inspection that is qualitative and quantitatively detecting is carried out to clinical and laboratory Ebola's culture available for preparing
Test agent, testing result provide laboratory diagnosis foundation for clinic.The present invention also completes the sequencing to monoclonal antibody, for list
Humanization modified, neutralizing antibody of the research and development with neutralization Ebola virus of clonal antibody sequence is Later development as clinic
Treatment ebola disease viral disease antibody establishes material base.
Preservation information
The culture title of preservation:Hybridoma cell strain ZJEB8-01;
Depositary institution's full name:China typical culture collection center;
Depositary institution is referred to as:CCTCC;
Preservation address:Wuhan, China Wuhan University;
Preservation date:On June 3rd, 2015;
Deposit number:CCTCC NO:C201583.
Description of the drawings
Fig. 1 is the immunoglobulin Subtype of monoclonal antibody.
Fig. 2 is the western figures that monoclonal antibody detects Ebola virus GP protein.
Fig. 3 is the sensitivity that monoclonal antibody detects Ebola virus GP protein.
Specific embodiment
The present invention is done with reference to embodiment and attached drawing and is further explained.The following example is merely to illustrate this hair
It is bright, but it is not used to limit the practical range of the present invention.
The preparation of the monoclonal antibody of 1 anti-Ebola GP albumen of embodiment
(1) mouse is immune:The BALB/C mice of 6 week old is selected to be immunized, first immunisation will be crosslinked the Ai Bo of KLH
Draw 20 peptides (the Ebola virus GP protein 412-431 amino acids sequences of virus GP protein:
DNDSTASDTPPATTAAGPLK) volume 1 is pressed with QuickAntibody-mouse5W:1 is uniformly mixed.Every BALB/C mice
0.1ml (20 peptide 100ug of Ebola's GP albumen), femoribus internus intramuscular injection.Press the same manner booster immunization one within 21st day
Pin.It adopts within 35th day micro tail blood and carries out ELISA measure, antibody titer reaches 1:32000, tail vein injection booster immunization one immediately
It is secondary, cell fusion was carried out after 3 days.
Wherein, 20 peptides of Ebola virus GP protein are by Solid phase synthesis, in the Peptide synthesizer of American AB I companies
Carried out on (431A), using Fmoc (9-fluorenylmethyloxycarbonyl) scheme, synthesis step according to ABI companies Peptide systhesis operation manual
It carries out.Through high-efficient liquid phase chromatogram purification, purity>95%, Sequence Identification passes through mass spectral analysis.
(2) culture of murine myeloma cell SP2/0:The SP2/0 myeloma cell strains from BALB/C mice to contain
10%FBS-DMEM medium cultures pass on, containing 5%CO2It is cultivated in 37 DEG C of incubators of saturated humidity.Merge the previous day passage
Cell enters exponential phase during ensureing to merge.
(3) cell fusion:Using BALB/C mice peritoneal macrophage as feeder cells, in fusion the previous day, inoculation
BALB/C mice peritoneal macrophage is in 96 well culture plates, the HAT medium cultures containing 20%FCS one day.Next day will be standby in (1)
Good mouse is put to death, and takes spleen, using pressure water flooding method separating spleen lymphocyte, with no blood after centrifuge washing cell 1~2 time
Clear RPMI 1640 culture mediums are resuspended.Murine myeloma cell SP2/0 in (2) is collected, centrifugation uses serum-free RPMI after washing 2 times
1640 culture medium is resuspended, as murine myeloma cell SP2/0 to be fused.With 1.0 × 108A immune mouse spleen lymph is thin
Born of the same parents and 1.0 × 107A murine myeloma cell SP2/0 mixing, is merged under 50%PEG6000 effects.After two kinds of mixing with cells
It washed once, supernatant is abandoned in centrifugation, is flicked tube wall and is hanged out cell (not liquid feeding body), with the 50%PEG6000 (pH of 37 DEG C of pre-temperatures
8.0) 0.8ml is added dropwise in 60~90 seconds in cell precipitation, gently shakes centrifuge tube therebetween, but is not blown and beaten, and stands 1 point
Clock, then by fast principle after first slow, in adding 1ml serum-frees RPMI 1640 in the 1st minute, in adding 2ml in the 2nd minute
Serum-free RPMI 1640 in adding 7ml serum-frees RPMI 1640 in the 3rd minute, is gradually added into 37 DEG C of pre-temperatures in later 1 minute
Serum-free RPMI164030~40ml.800 revs/min of low-speed centrifugals 5~10 minutes.Then the HAT cultures of 20%FCS are added in
Base is inoculated into 96 well culture plates added with feeder cells respectively, and the cell generally merged every time spreads 4 blocks of plates, puts 37 DEG C of 5%CO2
It is cultivated in incubator.
(4) screening of hybridoma:1/2 culture solution (HAT) was changed every 4 days once, uses the selection containing HT after 10 days instead
Property culture solution.Hybridoma after fusion lasts about greatly culture two weeks in the selective culture solution containing HT.In cell colony
When growing to appropriately sized (in 10 times of object Microscopic observations, cell clone size is advisable with taking a visual field), draw on culture solution
Clearly, ELISA, screening positive clone are done after appropriate dilution.Positive hybridoma clones are screened using ELISA indirect methods.Key step:
1. 0.01M pH9.6 carbonate buffer solutions dilute 20 peptides of Ebola's GP albumen, concentration 1000ng/ml, respectively at 96 hole enzyme marks
Plate adds in 0.1ml/ holes wrapper sheet, and 4 DEG C overnight;2. 20 board-washings of 0.01M pH7.4PBS-Tween are three times;3. use 2%BSA-0.01M
When the PBS closings 2 of pH 7.2 are small;4. ibid board-washing;5. add in 1:5 diluted hybridoma culture supernatants, 0.1ml/ holes are set simultaneously
Positive control (serum of immune mouse), negative control (SP2/0 culture supernatants) and blank control, when room temperature reaction 2 is small;⑥
Board-washing;7. plus 1:5000 diluted sheep anti-Mouse Ig (G+M)-HRP, 0.1ml/ holes, when room temperature reaction 1 is small;8. board-washing;9. it adds in
Substrate (TMB) room temperature is protected from light 5~10 minutes;⑩2M H2SO4 terminates reaction;450nm measures its OD value, with P/N >=2.1
For the positive.
(5) cloning of hybridoma:The colonized culture of hybridoma is carried out by limiting dilution assay, selects antibody
After the hybridoma holes cell of detection positive (20 peptides of Ebola's GP albumen of synthesis are positive) makees appropriate multiplication, accurate counting is thin
Born of the same parents.Being diluted to the cell suspension inoculation of 10/ml with complete 1640 culture medium, (feeder cells are still herein to existing feeder cells
BALB/C mice peritoneal macrophage) 96 well culture plates in, per hole 0.1ml, cell growth status is observed after 7-10 days, and is examined
Antibody level in supernatant is surveyed, selects 5 antibody titers highest, in the culture hole that single clone cell is grown, is made again gram
Longhua culture.The method can be repeated several times, until the positive porosity of hybridoma is 100%.Obtain hybridoma cell strain
ZJEB8-01。
(6) ascites is induced:1 week before hybridoma is inoculated with, norphytane every is injected intraperitoneally to BALB/C mice
0.5ml, then every inoculation 5.0 × 106A positive hybridoma cell collects ascites centrifugation, measures antibody titer after 10 days.
(7) purifying of monoclonal antibody:Ascites is purified using affinity purification (the crosslinked Sepharose of Protein G)
Middle monoclonal antibody.It after 1. ascites dilutes 3 times with cold Binding Buffer (combination buffer), is centrifuged in 4 DEG C of 10000rpm
15 minutes removal sediments.2. the affinity purification column of Sepharose-Protein G will be preinstalled with 10 times of bed volumes
Binding Buffer fully streams are washed.3. by diluted ascites upper prop, 8~10 drops of coutroi velocity/minute.4. the ascites that will be flowed through
Repeat upper prop once.5. it is fully washed with the Binding Buffer of 20 times of bed volumes, until it is small to flow through liquid A280 light absorption values
In 0.01.6. with the monoclonal antibody of Elution Buffer (elution buffer) elution of bound, the drop of coutroi velocity 8~10/point
Clock collects eluent in added in the collecting pipe of the kaliumphosphate buffer (pH7.9,0.5M) of 0.1ml, often pipe collects 0.5ml in advance
Eluent containing antibody is collected more than 20 pipes altogether.7. the absorbance of often pipe eluent is detected in A280nm, and it is big to collect light absorption value
In 0.2 eluent.8. the eluent of collection is placed in dialysis card, and dialyse in the PBS of 0.1MpH7.0.When 6 is small
It changes the liquid once, when dialysis 24 is small altogether.9. by the antibody-solutions dilution (1 after dialysis:100) after, protein content is surveyed in 280nm.⑩
The antibody of purifying is sub-packed in tubule, it is spare to be placed in low temperature refrigerator.
(8) the hypotype identification of monoclonal antibody:Using the mouse monoclonal antibody immunoglobulin parting of Serotec companies
Kit assay.It is detected after the monoclonal antibody of purifying is made appropriate dilution, operation is strictly carried out by kit specification.Experiment knot
Fruit is as shown in Figure 1, the monoclonal antibody of hybridoma cell strain ZJEB8-01 secretions is IgG1, κ type, with Ebola virus GP protein
Antigenic Peptide (412-431 amino acids sequence) have high specificity and sensitivity.Hybridoma cell strain ZJEB8-01 is
By China typical culture collection center (CCTCC) preservation;Address:Wuhan, China Wuhan University;Preservation date:June 3 in 2015
Day;Deposit number is:CCTCC NO:C201583.
Embodiment 2 carries out (qualitative) detection of identification of Ebola virus GP protein with the monoclonal antibody
Anti- Ebola GP protein monoclonal antibodies prepared by embodiment 1 can be used for (qualitative detection) identified, identification side
Method can be realized by following methods:
Western blot Western Blotting:Load Ebola's adenovirus recombinant vaccine of Ebola virus GP protein
It is cultivated in HEK-293 cells, culture cell pyrolysis liquid carries out Western Blotting detections with the monoclonal antibody, in corresponding position
Purpose band is presented, shows to detect the expression of Ebola virus GP protein.Specific steps:
(1) sds polyacrylamide gel electrophoresis:Method is referring to F. Ao Sibai etc.《Fine works molecular biology experiment guide》
(Science Press 1998).Using 10% separation gel and 5% concentration glue, deposition condition be voltage 150V, Bromophenol Blue dye band away from
1.5 centimetres from glue base or so termination electrophoresis.
(2) electrotransfer:Method is referring to F. Ao Sibai etc.《Fine works molecular biology experiment guide》(Science Press 1998).
Electricity consumption branch mode is transferred them on PVDF (0.45um) film.
(3) Western blotting:After electric transferring film, film in 5% skimmed milk power confining liquid room temperature closing 1 it is small when after, with this
Monoclonal antibody (1ug/ml) prepared by invention is as primary antibody, and when incubation at room temperature 2 is small or 4 DEG C are reacted overnight, and with TBST, (TBS adds in 0.5%
Tween-20) wash 3 times, each 10min.Using the sheep anti mouse IgM of horseradish peroxidase-labeled as secondary antibody, room temperature reaction
2h acts on 1min, in Full-automatic chemiluminescence imager (Bio-Rad VersaDoc after washing in aforementioned manners with ECL
5000MP) exposure image.
The result is shown in Fig. 2, GP-293 is the HEK-293 cytolytic proteins of Ebola GP genes transfection.293 turn for non-gene
The HEK-293 cytolytic proteins of dye do control and use.
3 monoclonal antibody of embodiment detects the sensitivity of Ebola virus GP protein
Anti- Ebola virus GP protein monoclonal antibody prepared by embodiment 1 can be used for quantitatively detecting angstrom of various expression
The rich level for drawing virus GP protein, can be realized by following methods:
Indirect elisa method:
1. detection sample is suitably diluted in 0.01M pH9.6 carbonate buffer solution coating buffers, 100ul/ holes, room temperature is incubated
Educate 2h or 4 DEG C of coating overnight.
2. it empties liquid and pats dry residual liquid, with 20 washing lotion board-washings of 0.01M pH7.4PBS-Tween three times.
3. when small with the PBS closings 1 of 2%BSA-0.01M pH 7.2.
4. ibid board-washing 3 times.
5. add in 1:The monoclonal antibody of 100 doubling dilutions, 0.1ml/ holes, when room temperature reaction 2 is small.
6. ibid after board-washing 3 times, add sheep anti-Mouse IgM-HRP, 0.1ml/ holes, when room temperature reaction 1 is small.
7. it after impregnating plate 5min with cleaning solution, ibid after board-washing 4 times, adds in substrate (TMB) room temperature and is protected from light 5~10 points
Clock.
⑧2M H2SO4 terminates reaction, and 450nm measures its OD value.
10. determine the sensitivity of monoclonal antibody detection Ebola virus GP protein.
The result is shown in Fig. 3 and table 1.Fig. 3 and table 1 correspond.First row represents extension rate, and secondary series is represented with non-gene
The HEK-293 cytolytic proteins of transfection exist as envelope antigen by the use of monoclonal antibody prepared by embodiment 1 as detection antibody
OD values under each dilution factor, the 3rd row represent anti-using the HEK-293 cytolytic proteins that Ebola GP genes transfect as coating
Original, by the use of monoclonal antibody prepared by embodiment 1 as detection antibody, the OD values under each dilution factor.4th row are represented with angstrom rich
The HEK-293 cytolytic proteins of GP genes transfection are drawn as envelope antigen, using mIgG as detection antibody under each dilution factor
OD values.The experimental results showed that the sensitivity of monoclonal antibody detection GP albumen prepared by embodiment 1 reaches 1:More than 10000.
Table 1
4 hybridoma cell strain ZJEB8-01 of embodiment, anti-Ebola virus GP protein monoclonal antibody sequences measure
The total serum IgE of hybridoma cell strain ZJEB8-01 is extracted, with universal primer reverse transcription into cDNA, then expands the light of antibody
Chain and heavy chain, separate light chain and heavy chain, are cloned on standard cloning vector and express, single bacterium colony PCR identification light chains and again
Chain, selects 5 light chains and the correct single bacterium colony of heavy chain length is sequenced, and 5 times sequencing result is almost identical, then it is assumed that is antibody
Real sequence.(sequencing procedure and antibody great expression commission Nanjing Jin Sirui biotechnologies company complete)
The gene order result that hybridoma cell strain ZJEB8-01 is obtained:Anti- Ebola virus GP protein monoclonal antibody weight
The long 399bp of chain encoding gene order, sequence such as SEQ ID NO:Shown in 1, wherein, 1-57 is leader, and 58-147 is framework region
1,148-162 is complementary determining region 1, and 163-204 is framework region 2, and 205-255 is complementary determining region 2, and 256-351 is framework region
3,352-366 be complementary determining region 3, and 367-399 is framework region 4;Anti- Ebola virus GP protein monoclonal antibody light chain coding
The long 396bp of gene order, sequence such as SEQ ID NO:Shown in 2, wherein, 1-60 is leader, and 61-129 is framework region 1,130-
177 be complementary determining region 1, and 178-222 is framework region 2, and 223-243 is complementary determining region 2, and 244-339 is framework region 3,340-
366 be complementary determining region 3, and 367-396 is framework region 4.Gene order according to being obtained is derived coded by the gene order
Heavy chain be made of 133 amino acid, sequence such as SEQ ID NO:Shown in 3;Light chain is made of 132 amino acid, sequence such as SEQ
ID NO:Shown in 4.
It is to be understood that the present invention is described with reference to most preferred embodiment, however in the above for having read the present invention
Afterwards, those skilled in the art can make various modifications or changes to the present invention, and such equivalent forms are equally fallen within appended by the application
Claims limited range.
Claims (5)
1. hybridoma cell strain ZJEB8-01, which is characterized in that it is preserved in China typical culture collection center CCTCC, protects
Hiding number is:CCTCC NO:C201583.
2. anti-Ebola virus GP protein monoclonal antibody, which is characterized in that it is by deposit number described in claim 1:
CCTCC NO:The hybridoma cell strain ZJEB8-01 of C201583 is generated.
3. hybridoma cell strain ZJEB8-01 described in claim 1 is in anti-Ebola virus GP protein monoclonal antibody is produced
Using.
4. the monoclonal antibody of the anti-Ebola virus GP protein described in claim 2 is preparing Ebola virus GP protein detection
Application in reagent.
5. anti-Ebola virus GP protein monoclonal antibody according to claim 4 is preparing Ebola virus GP protein inspection
Application in test agent, which is characterized in that the detection reagent detects sample by Western blot, enzyme-linked immunosorbent assay
The expression of middle Ebola virus GP protein.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510520454.6A CN105087497B (en) | 2015-08-21 | 2015-08-21 | Hybridoma cell strain ZJEB8-01, anti-Ebola virus GP protein monoclonal antibody, and preparation and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510520454.6A CN105087497B (en) | 2015-08-21 | 2015-08-21 | Hybridoma cell strain ZJEB8-01, anti-Ebola virus GP protein monoclonal antibody, and preparation and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105087497A CN105087497A (en) | 2015-11-25 |
CN105087497B true CN105087497B (en) | 2018-05-25 |
Family
ID=54568832
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510520454.6A Active CN105087497B (en) | 2015-08-21 | 2015-08-21 | Hybridoma cell strain ZJEB8-01, anti-Ebola virus GP protein monoclonal antibody, and preparation and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105087497B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111138529B (en) * | 2018-11-06 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | Monoclonal antibody 5E1 against GP2 subunit of EBOV with unique binding site |
CN111138528B (en) * | 2018-11-06 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | Monoclonal antibody 5A8 specifically binding to ebola virus glycoprotein glycan cap |
CN111138526B (en) * | 2018-11-06 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | Monoclonal antibody 2G1 for resisting subunit GP2 of Ebola virus glycoprotein and application thereof |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105542002B (en) * | 2016-02-01 | 2019-01-04 | 清华大学 | A kind of monoclonal antibody Q206 and application |
CN105601737B (en) * | 2016-02-01 | 2019-01-04 | 清华大学 | A kind of monoclonal antibody Q411 and application |
CN105622750B (en) * | 2016-02-01 | 2019-01-04 | 清华大学 | A kind of monoclonal antibody Q314 and application |
CN107541522A (en) * | 2016-06-24 | 2018-01-05 | 华中农业大学 | The monoclonal antibody of anti-Ebola virus GP protein and its application |
CN108250293B (en) * | 2018-02-11 | 2020-06-23 | 浙江大学 | anti-Ebola virus VP40 protein monoclonal antibody G7A6 and application thereof |
CN108484758B (en) * | 2018-02-11 | 2020-05-29 | 浙江大学 | anti-Ebola virus VP40 protein monoclonal antibody A2G7 and application thereof |
CN111138527B (en) * | 2018-11-06 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | Monoclonal antibody 4F1 for resisting subunit GP1 of Ebola virus glycoprotein and application thereof |
CN111138531B (en) * | 2018-11-06 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | Monoclonal antibody 8F9 specifically bound to GP1 subunit of EBOV and application |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001016183A1 (en) * | 1999-08-30 | 2001-03-08 | U.S. Army Medical Research Institute Of Infectious Diseases | Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein |
US6875433B2 (en) * | 2002-08-23 | 2005-04-05 | The United States Of America As Represented By The Secretary Of The Army | Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein |
-
2015
- 2015-08-21 CN CN201510520454.6A patent/CN105087497B/en active Active
Non-Patent Citations (3)
Title |
---|
Production of monoclonal antibodies and development of an antigen capture ELISA directed against the envelope glycoprotein GP of Ebola virus;Andreas Lucht等;《Med Microbiol Immunol》;20041231(第193期);全文 * |
埃博拉病毒包膜糖蛋白研究进展;丁国永等;《病毒学报》;20130331;第29卷(第2期);摘要 * |
抗埃博拉病毒 VP40 蛋白单克隆抗体的制备及在抗原捕捉ELISA中的应用;王淑杰等;《中国预防兽医学报》;20080430;第30卷(第4期);摘要 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111138529B (en) * | 2018-11-06 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | Monoclonal antibody 5E1 against GP2 subunit of EBOV with unique binding site |
CN111138528B (en) * | 2018-11-06 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | Monoclonal antibody 5A8 specifically binding to ebola virus glycoprotein glycan cap |
CN111138526B (en) * | 2018-11-06 | 2021-07-30 | 中国人民解放军军事科学院军事医学研究院 | Monoclonal antibody 2G1 for resisting subunit GP2 of Ebola virus glycoprotein and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN105087497A (en) | 2015-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105087497B (en) | Hybridoma cell strain ZJEB8-01, anti-Ebola virus GP protein monoclonal antibody, and preparation and application thereof | |
CN105112375B (en) | Hybridoma cell strain ZJED0-02, anti-Ebola virus GP protein monoclonal antibody, and preparation and application thereof | |
CN101985472B (en) | Monoclonal antibody TBCD6 resistant to mycobacterium tuberculosis CFP-10 and application | |
CN105801701B (en) | The heavy chain and light chain variable region of a kind of PCSK9 antibody and its application | |
CN105542014B (en) | TP recombinant antigen and preparation method and application thereof | |
CN108084255A (en) | A kind of preparation of canine recombinant c reactive protein and its monoclonal antibody | |
CN116836270B (en) | Monoclonal antibody of anti-bluetongue virus VP7 protein, preparation method and application | |
CN108484758B (en) | anti-Ebola virus VP40 protein monoclonal antibody A2G7 and application thereof | |
CN109180810A (en) | Specifically bind norovirus GI.1 genotype VP1 albumen and/or the antibody of VLP and its preparation method and application | |
CN106866820B (en) | Monoclonal antibody for capturing tumor cells and resisting human keratin 18 and application thereof | |
CN113604438B (en) | Monoclonal antibody for resisting tilapia lake virus, cell strain and application thereof | |
CN109295002B (en) | Hybridoma cell, monoclonal antibody, preparation method and application thereof | |
CN105695417B (en) | One plant of hybridoma cell strain for secreting Mycoplasma bovis monoclonal antibody and its application | |
CN102775486B (en) | The novel agent of monitoring injury of the kidney and test kit | |
CN108250293B (en) | anti-Ebola virus VP40 protein monoclonal antibody G7A6 and application thereof | |
CN114426576B (en) | Anti-H3N 2 influenza virus nucleoprotein monoclonal antibody ZJU-NP-A3 and application thereof in detection | |
CN113913389B (en) | Hybridoma cell strain, monoclonal antibody for resisting Brucella BAB antigen, and preparation and application thereof | |
CN101985473B (en) | Monoclonal antibody TBEF3 of tubercle bacillus-resistant ESAT-6 and application thereof | |
CN108794631A (en) | A kind of preparation method of the anti-mouse CD36 monoclonal antibodies of mouse | |
CN114456262A (en) | anti-H1N 1 influenza virus nucleoprotein monoclonal antibody ZJU-NP-A1 and application thereof in detection | |
Marriott et al. | Production and characterization of monoclonal antibodies to polyomavirus major capsid protein VP1 | |
Fasihi-Ramandi et al. | Production and characterization of monoclonal and polyclonal antibody against recombinant outer membrane protein | |
CN108424448B (en) | anti-Ebola virus VP40 protein monoclonal antibody F1B4 and application thereof | |
CN101985474B (en) | Monoclonal antibody TBCA6 resistant to mycobacterium tuberculosis CFP-10 and application | |
CN102533666A (en) | Orf virus (ORFV) protein ORFV059 monoclonal antibody hybridoma G3 and monoclonal antibody |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |